Nephrocalcinosis Management

Diagnostic Evaluation

The American College of Nephrology recommends obtaining serum calcium, phosphate, creatinine, intact PTH, and 25-OH vitamin D levels to evaluate for primary hyperparathyroidism, renal tubular acidosis (RTA), and vitamin D disorders 1, 2
The National Kidney Foundation suggests assessing for hypercalciuria using spot urine calcium/creatinine ratio 1, 2
Renal ultrasonography is recommended to confirm nephrocalcinosis extent and distribution 1, 2

The European Renal Association recommends aggressively increasing fluid intake to achieve urine output >2.5 liters daily to reduce urinary supersaturation and prevent stone formation 5, 2
The American College of Nephrology suggests limiting sodium intake to <100 mEq/day (<2,300 mg/day) to reduce urinary calcium excretion 5, 1, 2
Implementing moderate calcium restriction (400-800 mg/day) is recommended ONLY if hypercalciuria is documented, as excessive restriction worsens bone disease 1, 2

The National Kidney Foundation recommends administering potassium citrate 30-80 mEq/day in 3-4 divided doses to raise urinary pH to 6.0-6.5 and increase urinary citrate (a crystallization inhibitor) 5
For primary hyperoxaluria, urgently obtaining genetic testing is recommended if plasma oxalate is elevated or if eGFR <30 ml/min/1.73 m² with nephrocalcinosis 3, 4

The American College of Nephrology suggests obtaining single 24-hour urine collection at 6 months after initiating therapy to assess response 5
Annual 24-hour urine collections are recommended to assess adherence and metabolic response, with more frequent monitoring if stone activity continues 5
Renal ultrasonography every 12-24 months is recommended to assess nephrocalcinosis progression 1

The European Renal Association recommends referring to nephrology for progressive nephrocalcinosis despite initial management, eGFR <60 ml/min/1.73 m² or declining renal function, and complex metabolic disorders requiring specialized management 1, 2
Referring to endocrinology is recommended for primary hyperparathyroidism requiring surgical evaluation, suspected genetic hypophosphatemic disorders (XLH), and vitamin D metabolism disorders 1, 2